Korro Bio, Inc. — Form 8-K
Filed October 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Korro Bio initiated its ANCHOR Phase 1/2 clinical trial for KRRO-121 on October 5, 2026, dosing the first cohort of healthy volunteers with a single 2mg/kg dose in Australia. The trial enrolls up to 50 healthy volunteers (30 SAD, 20 MAD, placebo-controlled) followed by Part 2 with up to 15 UCD patients; UCD patient dosing expected H1 2027 with interim readout H2 2027. No dollar amounts, financing, or material partnerships disclosed.
Why this rating
First-in-human dosing is a major clinical milestone for a $89M clinical-stage biotech; validates lead program advancement and de-risks platform. Material progress but pre-revenue, early-stage trial with execution risk ahead.
See more from October 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.